Skip to main content
Clinical Trials/CTRI/2022/06/043130
CTRI/2022/06/043130
Completed
N/A

An Observational Study to Assess the Effect of the Accu-Chek® SugarView app (based on app version 4.0.3) on Diabetes Empowerment of Subjects with Type 2 Diabetes Mellitus (BEAT Accu-Chek SugarView India Study)

Roche Diabetes Care India Pvt Ltd0 sites100 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Sponsor
Roche Diabetes Care India Pvt Ltd
Enrollment
100
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
July 29, 2023
Last Updated
2 years ago
Study Type
Observational

Investigators

Sponsor
Roche Diabetes Care India Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\. Subject has provided his/her signed informed consent.
  • 2\. Subject is \= 18 years of age
  • 3\. Subject is diagnosed with diabetes type 2 and currently on exercise, diet or single or dual agent anti\-diabetic therapy (but not on insulin and anti\-diabetic drug with an hypoglycemic risk profile such as sulfonylureas)
  • 4\. Need to be empowered for disease self\-management
  • 5\. Willingness to adhere to the app
  • \- Never used a blood glucose meter for self\-testing of blood glucose before (SMBG naive)
  • 6\. Subject must have and can use a smartphone, and should complete training on usage of the application installed in smartphone
  • 7\. Subjects who are able to read and write in English language
  • 8\. Willing to participate in the study and comply with study procedures
  • 9\. Provide study demographics such as age, education level, gender, therapy type and occupation

Exclusion Criteria

  • 1\. Subject is pregnant or breastfeeding
  • 2\. Subject has incarceration or vision impairment not correctable with glasses or contact lenses
  • 3\. Subject is diagnosed with any clinically significant condition (e.g. infectious disease,
  • major organ system disease, such as gastroparesis or renal disease, psychosis or cognitive impairment), at investigator’s discretion
  • 4\. Subject does undergo chemotherapy or radiation therapy (self\-reported)
  • 5\. Subject is related to the investigator or research staff
  • 6\. Subject is using any other mobile device to monitor glucose levels
  • 7\. Subject shares phones with other persons

Outcomes

Primary Outcomes

Not specified

Similar Trials